Shares of BioNTech ( NASDAQ:BNTX) were falling 7.3% as of 11:24 a.m. EDT on Tuesday. The German biotech didn't announce any news. The most likely reason behind the decline was that Sanofi ( NASDAQ:SNY) is expanding its collaboration with Translate Bio ( NASDAQ:TBIO) to develop messenger RNA (mRNA) vaccines.
Full Answer
Should you buy bntx stock?
Overshadowed a bit by its much larger vaccine partner Pfizer, BioNTech is perhaps the most under-the-radar vaccine stock play, if there is such a thing. Only 10.5% of BNTX stock is held by institutions, and yet shares still more than doubled in the last year.
Why are Moderna shares down?
With the omicron variant proving to be highly infectious, there is a view among the scientific community, herd immunity could soon be reached, bringing the pandemic to an end. (Get Free Alerts for MRNA) shares were down 2.36% at $205.20. was slipping 2.01% at $198.90.
Why is Biotech stock down?
Nearly 400 publicly traded biotech companies have lost 40% or more of their value in just the past six months. The market's irrational behavior toward all things biotech, however, isn't necessarily a bad thing for patient investors.
Why are biotech stocks dropping?
With the biggest decline in more than two months, the shares of the Cambridge, Massachusetts-based biotech reached a 10-week low on above-average volume. The recent investor sentiment is not in ...
Why is BioNTech stock price dropping?
The good news regarding the drop in COVID-19 cases around the country is being perceived as bad news for BioNTech, whose Comirnaty COVID-19 vaccine it developed with Pfizer has sent the company to record revenue and profits in 2021.
Is BNTX stock a good buy now?
BioNTech has had an excellent 2021. 2022 and beyond will most likely not be this good, however. The company is very reliant on its COVID vax business today, but BNTX has some attractive pipeline candidates. For risk-hungry investors, BNTX might have value today.
Will BNTX go up?
The 12 analysts offering 12-month price forecasts for BioNTech SE have a median target of 246.83, with a high estimate of 357.21 and a low estimate of 171.16. The median estimate represents a +56.57% increase from the last price of 157.65.
Is it worth investing in BioNTech?
If you're an investor who typically invests in biotech stocks and is comfortable with the risks that they entail, I'd say that buying BioNTech today isn't a terrible decision. In the long run, its research and development activity should pay off, and it's in no great hurry for its pipeline projects to bear fruit.
Is BioNTech a hold?
BioNTech has received a consensus rating of Hold. The company's average rating score is 2.46, and is based on 6 buy ratings, 7 hold ratings, and no sell ratings.
Why is BioNTech up today?
Why BioNTech Stock Climbed Today. Shares of BioNTech (NASDAQ: BNTX) rose on Monday, following the release of the biotechnology company's first-quarter financial results. As of 2 p.m. ET, BioNTech's stock price was up more than 3% after rising as much as 7.3% earlier in the day.
Is BioNTech a buy Zacks?
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. The VGM Score are a complementary set of indicators to use alongside the Zacks Rank....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return4Sell5.79%5Strong Sell2.83%S&P50011.24%3 more rows
What is the forecast for Apple stock?
Stock Price Forecast The 39 analysts offering 12-month price forecasts for Apple Inc have a median target of 190.00, with a high estimate of 219.94 and a low estimate of 145.00. The median estimate represents a +38.55% increase from the last price of 137.13.
Who owns Pfizer stock?
The top shareholders of Pfizer are Frank A. D'amelio, John Douglas Young, Mikael Dolsten, Vanguard Group Inc., BlackRock Inc. (BLK), and State Street Corp.
How much is Pfizer making from vaccine?
In their Q3 financial statement, Pfizer forecast $36 billion in vaccine revenue for 2021. Gross profit from the revenue is split 50/50 with BioNTech. Pfizer guidance for their income before tax (after splitting profit with BioNTech) is 'High-20s as a Percentage of Revenues.
How do I buy BNTX?
How to Buy BioNTech (NASDAQ: BNTX) StockPick a Brokerage. As a retail investor, you cannot buy and sell shares of stock directly on an exchange like the New York Stock Exchange or the NASDAQ. ... Decide How Many Shares You Want. ... Choose Your Order Type. ... Execute Your Trade.
Is BioNTech a buy right now?
13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last twelve months. There are currently 7 hold r...
When is BioNTech's next earnings date?
BioNTech is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for BioNTech .
How were BioNTech's earnings last quarter?
BioNTech SE (NASDAQ:BNTX) issued its quarterly earnings results on Monday, May, 9th. The company reported $15.98 earnings per share for the quarter...
How often does BioNTech pay dividends? What is the dividend yield for BioNTech?
BioNTech declared a -- dividend on Thursday, April 28th. Investors of record on Friday, June 3rd will be paid a dividend of $1.5342 per share on Fr...
What price target have analysts set for BNTX?
13 brokers have issued 12 month price targets for BioNTech's shares. Their forecasts range from $146.00 to $359.00. On average, they anticipate Bio...
Who are BioNTech's key executives?
BioNTech's management team includes the following people: Prof. Ugur Sahin M.D. , Co-Founder, CEO & Chair of the Management Board (Age 56, Pay $...
What is Ugur Sahin's approval rating as BioNTech's CEO?
10 employees have rated BioNTech CEO Ugur Sahin on Glassdoor.com . Ugur Sahin has an approval rating of 89% among BioNTech's employees.
Who are some of BioNTech's key competitors?
Some companies that are related to BioNTech include Amgen (AMGN) , Gilead Sciences (GILD) , Moderna (MRNA) , Biogen (BIIB) , Seagen (SGEN) ,...
What other stocks do shareholders of BioNTech own?
Based on aggregate information from My MarketBeat watchlists, some companies that other BioNTech investors own include Moderna (MRNA) , Pfizer (P...
What is the ticker symbol for Biontech?
BioNTech trades on the NASDAQ under the ticker symbol "BNTX."
How much does Biontech make?
BioNTech has a market capitalization of $57.93 billion and generates $550.91 million in revenue each year. The company earns $17.36 million in net income (profit) each year or $0.07 on an earnings per share basis.
Where is Biontech located?
BioNTech's mailing address is AN DER GOLDGRUBE 12, MAINZ 2M, 55131. The company can be reached via phone at 49-61-31908-40, via email at [email protected], or via fax at 49-6131-908-4390.
Does Biontech pay dividends?
BioNTech does not currently pay a dividend.
What happened
Shares of several COVID-19 vaccine makers were sliding on Monday. BioNTech stock (NASDAQ: BNTX) was down 6.5% at 12:09 p.m. EDT. Shares of Moderna (NASDAQ: MRNA) had slipped 4.4%. Novavax (NASDAQ: NVAX) stock had fallen 6%.
So what
An end to the pandemic could lead to a significant reduction in sales for Moderna and BioNTech. It's unlikely that two doses of the company's vaccines will be needed then. It's still not clear whether ongoing boosters will be needed.
Now what
Expect all three stocks to remain highly volatile. Novavax could have the biggest potential catalysts on the way. The company hopes to file for Emergency Use Authorizations in several countries in the near future. Novavax also awaits Emergency Use Listing for its COVID-19 vaccine from the World Health Organization.
The Motley Fool
Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community.
Why are Biontech shares trading at a bargain?
BioNTech's shares are trading at a seeming bargain because investors aren't sure how much recurring revenue the company will be able to count on after 2022. If booster doses are needed going forward, BioNTech's future sales could be massive for a long time to come. Yahoo Finance Video • 2 days ago.
Is Pfizer developing a delta booster?
Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) announced Thursday that they are developing a COVID-19 booster dose intended to target the delta variant. What Happened: The companies expect to shortly seek U.S. authorization for a third dose of its vaccine. The companies said that though they believe the third shot of their current two-dose vaccine has the potential to preserve the "highest levels" of protection against all currently known variants, including delta, they are "remaining vig
Is Pfizer the IBD stock?
Pfizer is the IBD Stock Of The Day as scientists grapple with a new variant that could undo Covid vaccines. Pfizer may be ready for it.
Recently Viewed Tickers
Visit a quote page and your recently viewed tickers will be displayed here.
BioNTech SE ADR
BioNTech SE is a next-generation immunotherapy company, which treats cancer and other serious diseases. It exploits an array of discovery and therapeutic drug platforms for the development of novel biopharmaceuticals.
